Les cancers bronchiques à petites cellules

Because of a reduction in the proportion of SCLC, the number of trials addressing SCLC is decreasing. However, there are still many unanswered questions and better survival results are needed. Efforts for molecular subtyping of SCLC are ongoing, with the parallel search for therapies targeting the identified biomarkers. © 2013 SPLF. Published by Elsevier Masson SAS. All rights reserved.